Barbara Ryan, a director at MiNK Therapeutics, Inc. (NASDAQ: INKT), has executed a divestment of common stock valued at $19,141. The transaction took place on June 4, 2026, involving the disposal of 1,500 shares. The sales were processed through two direct transactions at prices ranging from $12.6835 to $12.7995 per share. These shares were originally received by Ms. Ryan as compensation for her services rendered as a member of MiNK Therapeutics, Inc.'s Board of Directors. Following these transactions, Ms. Ryan directly holds 21,969 shares of MiNK Therapeutics common stock.
The sale comes as INKT shares closed at $12.75, though the stock has delivered a 63% return over the past year. According to InvestingPro analysis, the stock appears overvalued at current levels. Investors seeking deeper insights can access comprehensive analysis through INKT's Pro Research Report, available for this and 1,400+ other US equities.
In other recent news, MiNK Therapeutics reported its Q1 2026 earnings, revealing a cash balance of $9.5 million and a net loss of $2.7 million, or $0.57 per share. This marks an improvement compared to the previous year, showcasing the company's disciplined capital management and strategic progress in its clinical programs. Additionally, MiNK Therapeutics announced the dosing of the first patient in its Phase 2 clinical trial for agenT-797, targeting severe acute lung injury, following approval from the Ministry of Health of Ukraine.
Meanwhile, Agenus Inc. shared results from its Phase 1b trial of botensilimab and balstilimab for patients with hepatocellular carcinoma. The study, involving 19 patients who had progressed after prior immunotherapy, was published in the journal Liver Cancer. These patients had previously received various treatments, including anti-PD-(L)1 therapy and tyrosine kinase inhibitors. Both MiNK Therapeutics and Agenus Inc. are making strides in their respective clinical trials, contributing to advancements in treatment options for critical illnesses.
MiNK Therapeutics
Follow
Analyze INKT
Included in our AI-picked strategies
Review strategies
11.87
▼-0.8800(-6.90%)
Closed
·15:59:59
·USD
11.36
▼-0.5100(-4.30%)
After Hours
·18:07:25
1D
1W
6M
1Y
5Y
Max
Created with Highcharts 11.4.8
14:00
15:00
16:00
17:00
18:00
19:00
19:30
11
12
Analyze INKT
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
See the trade on INKT, but can't pull the trigger?
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally